GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » Sloan Ratio %

Revive Therapeutics (XCNQ:RVV) Sloan Ratio % : 0.00% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Revive Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

As of Dec. 2023, Revive Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Revive Therapeutics Sloan Ratio % Historical Data

The historical data trend for Revive Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Sloan Ratio % Chart

Revive Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.14 -36.41 -30.51 - -

Revive Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revive Therapeutics's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Sloan Ratio % falls into.



Revive Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Revive Therapeutics's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(-6.321--6.026
-0)/14.252
=-2.07%

Revive Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-2.687--2.255
-0)/12.877
=-3.35%

Revive Therapeutics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -1.525 (Dec. 2022 ) + 0 (Jun. 2023 ) + -0.391 (Sep. 2023 ) + -0.771 (Dec. 2023 ) = C$-2.69 Mil.
Revive Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -0.876 (Dec. 2022 ) + 0 (Jun. 2023 ) + -0.496 (Sep. 2023 ) + -0.883 (Dec. 2023 ) = C$-2.26 Mil.
Revive Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Dec. 2022 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics  (XCNQ:RVV) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Revive Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Revive Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics (XCNQ:RVV) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
Executives
Michael Frank Director, Senior Officer

Revive Therapeutics (XCNQ:RVV) Headlines

No Headlines